Section 1. Identification

1.1 Product identifier

Product name : MVP Total RNA - Human HeLa S3 Cells with and without PMA treatment, Part Number 540113

Part No. (Chemical Kit) : 540113

Part No. : MVP Total RNA, Human HeLa S3 Cells 540087-41
          MVP Total RNA, Human HeLa S3 Cells, PMA-treated 540097-41

Validation date : 2015-09-01

1.2 Relevant identified uses of the substance or mixture and uses advised against

Material uses : Analytical reagent.

MVP Total RNA, Human HeLa S3 Cells 0.025 ml
MVP Total RNA, Human HeLa S3 Cells, PMA-treated 0.028 ml

1.3 Details of the supplier of the safety data sheet

Supplier/Manufacturer : Agilent Technologies, Inc.
                      5301 Stevens Creek Blvd
                      Santa Clara, CA 95051, USA
                      800-227-9770

1.4 Emergency telephone number

In case of emergency : CHEMTREC®: 1-800-424-9300

Section 2. Hazards identification

2.1 Classification of the substance or mixture

OSHA/HCS status : MVP Total RNA, Human HeLa S3 Cells

While this material is not considered hazardous by the OSHA Hazard Communication Standard (29 CFR 1910.1200), this SDS contains valuable information critical to the safe handling and proper use of the product. This SDS should be retained and available for employees and other users of this product.

MVP Total RNA, Human HeLa S3 Cells, PMA-treated

While this material is not considered hazardous by the OSHA Hazard Communication Standard (29 CFR 1910.1200), this SDS contains valuable information critical to the safe handling and proper use of the product. This SDS should be retained and available for employees and other users of this product.

Classification of the substance or mixture

Not classified.

2.2 GHS label elements

Signal word : MVP Total RNA, Human HeLa S3 Cells
              No signal word.
              MVP Total RNA, Human HeLa S3 Cells, PMA-treated
              No signal word.

Date of issue : 09/01/2015
Section 2. Hazards identification

**Hazard statements**
- MVP Total RNA, Human HeLa S3 Cells: No known significant effects or critical hazards.
- MVP Total RNA, Human HeLa S3 Cells, PMA-treated: No known significant effects or critical hazards.

**Precautionary statements**

**Prevention**
- MVP Total RNA, Human HeLa S3 Cells: Not applicable.
- MVP Total RNA, Human HeLa S3 Cells, PMA-treated: Not applicable.

**Response**
- MVP Total RNA, Human HeLa S3 Cells: Not applicable.
- MVP Total RNA, Human HeLa S3 Cells, PMA-treated: Not applicable.

**Storage**
- MVP Total RNA, Human HeLa S3 Cells: Not applicable.
- MVP Total RNA, Human HeLa S3 Cells, PMA-treated: Not applicable.

**Disposal**
- MVP Total RNA, Human HeLa S3 Cells: Not applicable.
- MVP Total RNA, Human HeLa S3 Cells, PMA-treated: Not applicable.

**Supplemental label elements**
- MVP Total RNA, Human HeLa S3 Cells: None known.
- MVP Total RNA, Human HeLa S3 Cells, PMA-treated: None known.

2.3 Other hazards

**Hazards not otherwise classified**
- MVP Total RNA, Human HeLa S3 Cells: None known.
- MVP Total RNA, Human HeLa S3 Cells, PMA-treated: None known.

Section 3. Composition/information on ingredients

**Substance/mixture**
- MVP Total RNA, Human HeLa S3 Cells: Mixture
- MVP Total RNA, Human HeLa S3 Cells, PMA-treated: Mixture

Any concentration shown as a range is to protect confidentiality or is due to batch variation.

There are no ingredients present which, within the current knowledge of the supplier and in the concentrations applicable, are classified as hazardous to health or the environment and hence require reporting in this section. Occupational exposure limits, if available, are listed in Section 8.

Section 4. First aid measures

4.1 Description of necessary first aid measures

**Eye contact**
- MVP Total RNA, Human HeLa S3 Cells: Immediately flush eyes with plenty of water, occasionally lifting the upper and lower eyelids. Check for and remove any contact lenses. Get medical attention if irritation occurs.
- MVP Total RNA, Human HeLa S3 Cells, PMA-treated: Immediately flush eyes with plenty of water, occasionally lifting the upper and lower eyelids. Check for and remove any contact lenses. Get medical attention if irritation occurs.
## Section 4. First aid measures

### Inhalation
- **MVP Total RNA, Human HeLa S3 Cells**
  - Remove victim to fresh air and keep at rest in a position comfortable for breathing. Get medical attention if symptoms occur.
- **MVP Total RNA, Human HeLa S3 Cells, PMA-treated**
  - Remove victim to fresh air and keep at rest in a position comfortable for breathing. Get medical attention if symptoms occur.

### Skin contact
- **MVP Total RNA, Human HeLa S3 Cells**
  - Wash out mouth with water. Remove victim to fresh air and keep at rest in a position comfortable for breathing. Get medical attention if symptoms occur.
- **MVP Total RNA, Human HeLa S3 Cells, PMA-treated**
  - Wash out mouth with water. Remove victim to fresh air and keep at rest in a position comfortable for breathing. Get medical attention if symptoms occur.

### Ingestion
- **MVP Total RNA, Human HeLa S3 Cells**
  - Wash out mouth with water. Remove victim to fresh air and keep at rest in a position comfortable for breathing. If material has been swallowed and the exposed person is conscious, give small quantities of water to drink. Do not induce vomiting unless directed to do so by medical personnel. Get medical attention if symptoms occur.
- **MVP Total RNA, Human HeLa S3 Cells, PMA-treated**
  - Wash out mouth with water. Remove victim to fresh air and keep at rest in a position comfortable for breathing. If material has been swallowed and the exposed person is conscious, give small quantities of water to drink. Do not induce vomiting unless directed to do so by medical personnel. Get medical attention if symptoms occur.

### 4.2 Most important symptoms/effects, acute and delayed

#### Potential acute health effects

**Eye contact**
- **MVP Total RNA, Human HeLa S3 Cells**
  - No known significant effects or critical hazards.
- **MVP Total RNA, Human HeLa S3 Cells, PMA-treated**
  - No known significant effects or critical hazards.

**Inhalation**
- **MVP Total RNA, Human HeLa S3 Cells**
  - No known significant effects or critical hazards.
- **MVP Total RNA, Human HeLa S3 Cells, PMA-treated**
  - No known significant effects or critical hazards.

**Skin contact**
- **MVP Total RNA, Human HeLa S3 Cells**
  - No known significant effects or critical hazards.
- **MVP Total RNA, Human HeLa S3 Cells, PMA-treated**
  - No known significant effects or critical hazards.

**Ingestion**
- **MVP Total RNA, Human HeLa S3 Cells**
  - No known significant effects or critical hazards.
- **MVP Total RNA, Human HeLa S3 Cells, PMA-treated**
  - No known significant effects or critical hazards.

#### Over-exposure signs/symptoms

**Eye contact**
- **MVP Total RNA, Human HeLa S3 Cells**
  - No specific data.
- **MVP Total RNA, Human HeLa S3 Cells, PMA-treated**
  - No specific data.

**Inhalation**
- **MVP Total RNA, Human HeLa S3 Cells**
  - No specific data.
- **MVP Total RNA, Human HeLa S3 Cells, PMA-treated**
  - No specific data.
Section 4. First aid measures

**Skin contact**
- MVP Total RNA, Human HeLa S3 Cells
- MVP Total RNA, Human HeLa S3 Cells, PMA-treated

**Ingestion**
- MVP Total RNA, Human HeLa S3 Cells
- MVP Total RNA, Human HeLa S3 Cells, PMA-treated

4.3 Indication of immediate medical attention and special treatment needed, if necessary

**Notes to physician**
- MVP Total RNA, Human HeLa S3 Cells
- MVP Total RNA, Human HeLa S3 Cells, PMA-treated

**Specific treatments**
- MVP Total RNA, Human HeLa S3 Cells
- MVP Total RNA, Human HeLa S3 Cells, PMA-treated

**Protection of first-aiders**
- MVP Total RNA, Human HeLa S3 Cells
- MVP Total RNA, Human HeLa S3 Cells, PMA-treated

See toxicological information (Section 11)

Section 5. Fire-fighting measures

5.1 Extinguishing media

**Suitable extinguishing media**
- MVP Total RNA, Human HeLa S3 Cells
- MVP Total RNA, Human HeLa S3 Cells, PMA-treated

**Unsuitable extinguishing media**
- MVP Total RNA, Human HeLa S3 Cells
- MVP Total RNA, Human HeLa S3 Cells, PMA-treated

5.2 Special hazards arising from the substance or mixture

**Specific hazards arising from the chemical**
- MVP Total RNA, Human HeLa S3 Cells
- MVP Total RNA, Human HeLa S3 Cells, PMA-treated

**Hazardous thermal decomposition products**
- MVP Total RNA, Human HeLa S3 Cells
- MVP Total RNA, Human HeLa S3 Cells, PMA-treated

5.3 Advice for firefighters

Date of issue: 09/01/2015
Section 5. Fire-fighting measures

Special protective actions for fire-fighters
- MVP Total RNA, Human HeLa S3 Cells
  Promptly isolate the scene by removing all persons from the vicinity of the incident if there is a fire. No action shall be taken involving any personal risk or without suitable training.
- MVP Total RNA, Human HeLa S3 Cells, PMA-treated
  Promptly isolate the scene by removing all persons from the vicinity of the incident if there is a fire. No action shall be taken involving any personal risk or without suitable training.

Special protective equipment for fire-fighters
- MVP Total RNA, Human HeLa S3 Cells
  Fire-fighters should wear appropriate protective equipment and self-contained breathing apparatus (SCBA) with a full face-piece operated in positive pressure mode.
- MVP Total RNA, Human HeLa S3 Cells, PMA-treated
  Fire-fighters should wear appropriate protective equipment and self-contained breathing apparatus (SCBA) with a full face-piece operated in positive pressure mode.

Section 6. Accidental release measures

6.1 Personal precautions, protective equipment and emergency procedures

For non-emergency personnel
- MVP Total RNA, Human HeLa S3 Cells
  No action shall be taken involving any personal risk or without suitable training. Evacuate surrounding areas. Keep unnecessary and unprotected personnel from entering. Do not touch or walk through spilled material. Put on appropriate personal protective equipment.
- MVP Total RNA, Human HeLa S3 Cells, PMA-treated
  No action shall be taken involving any personal risk or without suitable training. Evacuate surrounding areas. Keep unnecessary and unprotected personnel from entering. Do not touch or walk through spilled material. Put on appropriate personal protective equipment.

For emergency responders
- MVP Total RNA, Human HeLa S3 Cells
  If specialised clothing is required to deal with the spillage, take note of any information in Section 8 on suitable and unsuitable materials. See also the information in "For non-emergency personnel".
- MVP Total RNA, Human HeLa S3 Cells, PMA-treated
  If specialised clothing is required to deal with the spillage, take note of any information in Section 8 on suitable and unsuitable materials. See also the information in "For non-emergency personnel".

6.2 Environmental precautions
- MVP Total RNA, Human HeLa S3 Cells
  Avoid dispersal of spilled material and runoff and contact with soil, waterways, drains and sewers. Inform the relevant authorities if the product has caused environmental pollution (sewers, waterways, soil or air).
- MVP Total RNA, Human HeLa S3 Cells, PMA-treated
  Avoid dispersal of spilled material and runoff and contact with soil, waterways, drains and sewers. Inform the relevant authorities if the product has caused environmental pollution (sewers, waterways, soil or air).

6.3 Methods and materials for containment and cleaning up
### Section 6. Accidental release measures

**Methods for cleaning up**
- **MVP Total RNA, Human HeLa S3 Cells**
  - Stop leak if without risk. Move containers from spill area. Dilute with water and mop up if water-soluble. Alternatively, or if water-insoluble, absorb with an inert dry material and place in an appropriate waste disposal container. Dispose of via a licensed waste disposal contractor.
- **MVP Total RNA, Human HeLa S3 Cells, PMA-treated**
  - Stop leak if without risk. Move containers from spill area. Dilute with water and mop up if water-soluble. Alternatively, or if water-insoluble, absorb with an inert dry material and place in an appropriate waste disposal container. Dispose of via a licensed waste disposal contractor.

### Section 7. Handling and storage

**7.1 Precautions for safe handling**
- **Protective measures**
  - **MVP Total RNA, Human HeLa S3 Cells**
    - Put on appropriate personal protective equipment (see Section 8).
  - **MVP Total RNA, Human HeLa S3 Cells, PMA-treated**
    - Put on appropriate personal protective equipment (see Section 8).
- **Advice on general occupational hygiene**
  - **MVP Total RNA, Human HeLa S3 Cells**
    - Eating, drinking and smoking should be prohibited in areas where this material is handled, stored and processed. Workers should wash hands and face before eating, drinking and smoking. Remove contaminated clothing and protective equipment before entering eating areas. See also Section 8 for additional information on hygiene measures.
  - **MVP Total RNA, Human HeLa S3 Cells, PMA-treated**
    - Eating, drinking and smoking should be prohibited in areas where this material is handled, stored and processed. Workers should wash hands and face before eating, drinking and smoking. Remove contaminated clothing and protective equipment before entering eating areas. See also Section 8 for additional information on hygiene measures.

**7.2 Conditions for safe storage, including any incompatibilities**
- **MVP Total RNA, Human HeLa S3 Cells**
  - Store in accordance with local regulations. Store in original container protected from direct sunlight in a dry, cool and well-ventilated area, away from incompatible materials (see Section 10) and food and drink. Keep container tightly closed and sealed until ready for use. Containers that have been opened must be carefully resealed and kept upright to prevent leakage. Do not store in unlabelled containers. Use appropriate containment to avoid environmental contamination.
- **MVP Total RNA, Human HeLa S3 Cells, PMA-treated**
  - Store in accordance with local regulations. Store in original container protected from direct sunlight in a dry, cool and well-ventilated area, away from incompatible materials (see Section 10) and food and drink. Keep container tightly closed and sealed until ready for use. Containers that have been opened must be carefully resealed and kept upright to prevent leakage. Do not store in unlabelled containers. Use appropriate containment to avoid environmental contamination.
Section 7. Handling and storage

Recommendations:  
- MVP Total RNA, Human HeLa S3 Cells  
- MVP Total RNA, Human HeLa S3 Cells, PMA-treated  
Industrial applications, Professional applications.

Industrial sector specific solutions:  
- MVP Total RNA, Human HeLa S3 Cells  
- MVP Total RNA, Human HeLa S3 Cells, PMA-treated  
Not applicable.

Section 8. Exposure controls/personal protection

8.1 Control parameters

Occupational exposure limits

<table>
<thead>
<tr>
<th>Ingredient name</th>
<th>Exposure limits</th>
</tr>
</thead>
<tbody>
<tr>
<td>None.</td>
<td>None.</td>
</tr>
</tbody>
</table>

8.2 Exposure controls

Appropriate engineering controls:  
- Good general ventilation should be sufficient to control worker exposure to airborne contaminants.

Environmental exposure controls:  
- Emissions from ventilation or work process equipment should be checked to ensure they comply with the requirements of environmental protection legislation. In some cases, fume scrubbers, filters or engineering modifications to the process equipment will be necessary to reduce emissions to acceptable levels.

Individual protection measures

Hygiene measures:  
- Wash hands, forearms and face thoroughly after handling chemical products, before eating, smoking and using the lavatory and at the end of the working period. 
- Appropriate techniques should be used to remove potentially contaminated clothing. 
- Wash contaminated clothing before reusing. 
- Ensure that eyewash stations and safety showers are close to the workstation location.

Eye/face protection:  
- Safety eyewear complying with an approved standard should be used when a risk assessment indicates this is necessary to avoid exposure to liquid splashes, mists, gases or dusts. If contact is possible, the following protection should be worn, unless the assessment indicates a higher degree of protection: safety glasses with side-shields.

Skin protection

Hand protection:  
- Chemical-resistant, impervious gloves complying with an approved standard should be worn at all times when handling chemical products if a risk assessment indicates this is necessary.

Body protection:  
- Personal protective equipment for the body should be selected based on the task being performed and the risks involved and should be approved by a specialist before handling this product.

Other skin protection:  
- Appropriate footwear and any additional skin protection measures should be selected based on the task being performed and the risks involved and should be approved by a specialist before handling this product.

Respiratory protection:  
- Use a properly fitted, air-purifying or air-fed respirator complying with an approved standard if a risk assessment indicates this is necessary. Respirator selection must be based on known or anticipated exposure levels, the hazards of the product and the safe working limits of the selected respirator.
## Section 9. Physical and chemical properties

### 9.1 Information on basic physical and chemical properties

<table>
<thead>
<tr>
<th>Property</th>
<th>MVP Total RNA, Human HeLa S3 Cells</th>
<th>MVP Total RNA, Human HeLa S3 Cells, PMA-treated</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Physical state</strong></td>
<td>Liquid</td>
<td>Liquid</td>
</tr>
<tr>
<td><strong>Color</strong></td>
<td>Not available.</td>
<td>Not available.</td>
</tr>
<tr>
<td><strong>Odor</strong></td>
<td>Not available.</td>
<td>Not available.</td>
</tr>
<tr>
<td><strong>Odor threshold</strong></td>
<td>Not available.</td>
<td>Not available.</td>
</tr>
<tr>
<td><strong>pH</strong></td>
<td>8</td>
<td>8</td>
</tr>
<tr>
<td><strong>Melting point</strong></td>
<td>0°C (32°F)</td>
<td>0°C (32°F)</td>
</tr>
<tr>
<td><strong>Boiling point</strong></td>
<td>100°C (212°F)</td>
<td>100°C (212°F)</td>
</tr>
<tr>
<td><strong>Flash point</strong></td>
<td>Not applicable.</td>
<td>Not applicable.</td>
</tr>
<tr>
<td><strong>Evaporation rate</strong></td>
<td>Not available.</td>
<td>Not available.</td>
</tr>
<tr>
<td><strong>Flammability (solid, gas)</strong></td>
<td>Not applicable.</td>
<td>Not applicable.</td>
</tr>
<tr>
<td><strong>Lower and upper explosive (flammable) limits</strong></td>
<td>Not available.</td>
<td>Not available.</td>
</tr>
<tr>
<td><strong>Vapor pressure</strong></td>
<td>Not available.</td>
<td>Not available.</td>
</tr>
<tr>
<td><strong>Vapor density</strong></td>
<td>Not available.</td>
<td>Not available.</td>
</tr>
</tbody>
</table>

**Date of issue:** 09/01/2015
Section 9. Physical and chemical properties

Relative density
MVP Total RNA, Human HeLa S3 Cells: Not available.
MVP Total RNA, Human HeLa S3 Cells, PMA-treated: Not available.

Solubility
MVP Total RNA, Human HeLa S3 Cells: Easily soluble in the following materials: cold water and hot water.
MVP Total RNA, Human HeLa S3 Cells, PMA-treated: Easily soluble in the following materials: cold water and hot water.

Partition coefficient: n-octanol/water
MVP Total RNA, Human HeLa S3 Cells: Not available.
MVP Total RNA, Human HeLa S3 Cells, PMA-treated: Not available.

Auto-ignition temperature
MVP Total RNA, Human HeLa S3 Cells: Not available.
MVP Total RNA, Human HeLa S3 Cells, PMA-treated: Not available.

Decomposition temperature
MVP Total RNA, Human HeLa S3 Cells: Not available.
MVP Total RNA, Human HeLa S3 Cells, PMA-treated: Not available.

Viscosity
MVP Total RNA, Human HeLa S3 Cells: Not available.
MVP Total RNA, Human HeLa S3 Cells, PMA-treated: Not available.

Section 10. Stability and reactivity

10.1 Reactivity
MVP Total RNA, Human HeLa S3 Cells: No specific test data related to reactivity available for this product or its ingredients.
MVP Total RNA, Human HeLa S3 Cells, PMA-treated: No specific test data related to reactivity available for this product or its ingredients.

10.2 Chemical stability
MVP Total RNA, Human HeLa S3 Cells: The product is stable.
MVP Total RNA, Human HeLa S3 Cells, PMA-treated: The product is stable.

10.3 Possibility of hazardous reactions
MVP Total RNA, Human HeLa S3 Cells: Under normal conditions of storage and use, hazardous reactions will not occur.
MVP Total RNA, Human HeLa S3 Cells, PMA-treated: Under normal conditions of storage and use, hazardous reactions will not occur.

10.4 Conditions to avoid
MVP Total RNA, Human HeLa S3 Cells: No specific data.
MVP Total RNA, Human HeLa S3 Cells, PMA-treated: No specific data.

10.5 Incompatible materials
MVP Total RNA, Human HeLa S3 Cells: May react or be incompatible with oxidizing materials.
MVP Total RNA, Human HeLa S3 Cells, PMA-treated: May react or be incompatible with oxidizing materials.
Section 10. Stability and reactivity

10.6 Hazardous decomposition products

- MVP Total RNA, Human HeLa S3 Cells
- MVP Total RNA, Human HeLa S3 Cells, PMA-treated

Under normal conditions of storage and use, hazardous decomposition products should not be produced.

Section 11. Toxicological information

11.1 Information on toxicological effects

Acute toxicity
Not available.

Irritation/Corrosion
Not available.

Sensitization
Not available.

Mutagenicity
Not available.

Carcinogenicity
Not available.

Reproductive toxicity
Not available.

Teratogenicity
Not available.

Specific target organ toxicity (single exposure)
Not available.

Specific target organ toxicity (repeated exposure)
Not available.

Aspiration hazard
Not available.

Information on the likely routes of exposure

- MVP Total RNA, Human HeLa S3 Cells
- MVP Total RNA, Human HeLa S3 Cells, PMA-treated

Not available.

Potential acute health effects

Eye contact

- MVP Total RNA, Human HeLa S3 Cells
- MVP Total RNA, Human HeLa S3 Cells, PMA-treated

No known significant effects or critical hazards.

Inhalation

- MVP Total RNA, Human HeLa S3 Cells
- MVP Total RNA, Human HeLa S3 Cells, PMA-treated

No known significant effects or critical hazards.

Skin contact

- MVP Total RNA, Human HeLa S3 Cells
- MVP Total RNA, Human HeLa S3 Cells, PMA-treated

No known significant effects or critical hazards.

Date of issue: 09/01/2015
Section 11. Toxicological information

**Ingestion**
- MVP Total RNA, Human HeLa S3 Cells
- No known significant effects or critical hazards.
- MVP Total RNA, Human HeLa S3 Cells, PMA-treated
- No known significant effects or critical hazards.

**Symptoms related to the physical, chemical and toxicological characteristics**

**Eye contact**
- MVP Total RNA, Human HeLa S3 Cells
- No specific data.
- MVP Total RNA, Human HeLa S3 Cells, PMA-treated
- No specific data.

**Inhalation**
- MVP Total RNA, Human HeLa S3 Cells
- No specific data.
- MVP Total RNA, Human HeLa S3 Cells, PMA-treated
- No specific data.

**Skin contact**
- MVP Total RNA, Human HeLa S3 Cells
- No specific data.
- MVP Total RNA, Human HeLa S3 Cells, PMA-treated
- No specific data.

**Ingestion**
- MVP Total RNA, Human HeLa S3 Cells
- No specific data.
- MVP Total RNA, Human HeLa S3 Cells, PMA-treated
- No specific data.

**Delayed and immediate effects and also chronic effects from short and long term exposure**

**Short term exposure**

**Potential immediate effects**
- Not available.

**Potential delayed effects**
- Not available.

**Long term exposure**

**Potential immediate effects**
- Not available.

**Potential delayed effects**
- Not available.

**Potential chronic health effects**

**General**
- MVP Total RNA, Human HeLa S3 Cells
- No known significant effects or critical hazards.
- MVP Total RNA, Human HeLa S3 Cells, PMA-treated
- No known significant effects or critical hazards.

**Carcinogenicity**
- MVP Total RNA, Human HeLa S3 Cells
- No known significant effects or critical hazards.
- MVP Total RNA, Human HeLa S3 Cells, PMA-treated
- No known significant effects or critical hazards.

**Mutagenicity**
- MVP Total RNA, Human HeLa S3 Cells
- No known significant effects or critical hazards.
- MVP Total RNA, Human HeLa S3 Cells, PMA-treated
- No known significant effects or critical hazards.

**Teratogenicity**
- MVP Total RNA, Human HeLa S3 Cells
- No known significant effects or critical hazards.
- MVP Total RNA, Human HeLa S3 Cells, PMA-treated
- No known significant effects or critical hazards.

**Developmental effects**
- MVP Total RNA, Human HeLa S3 Cells
- No known significant effects or critical hazards.
- MVP Total RNA, Human HeLa S3 Cells, PMA-treated
- No known significant effects or critical hazards.
Section 11. Toxicological information

Fertility effects: MVP Total RNA, Human HeLa S3 Cells, No known significant effects or critical hazards.

MVP Total RNA, Human HeLa S3 Cells, PMA-treated, No known significant effects or critical hazards.

Numerical measures of toxicity

Acute toxicity estimates
Not available.

Section 12. Ecological information

12.1 Toxicity
Not available.

12.2 Persistence and degradability
Not available.

12.3 Bioaccumulative potential
Not available.

12.4 Mobility in soil
Soil/water partition coefficient (K_{oc}): Not available.

12.5 Other adverse effects: No known significant effects or critical hazards.

Section 13. Disposal considerations

13.1 Waste treatment methods
Disposal methods: The generation of waste should be avoided or minimized wherever possible. Disposal of this product, solutions and any by-products should at all times comply with the requirements of environmental protection and waste disposal legislation and any regional local authority requirements. Dispose of surplus and non-recyclable products via a licensed waste disposal contractor. Waste should not be disposed of untreated to the sewer unless fully compliant with the requirements of all authorities with jurisdiction. Waste packaging should be recycled. Incineration or landfill should only be considered when recycling is not feasible. This material and its container must be disposed of in a safe way. Empty containers or liners may retain some product residues. Avoid dispersal of spilled material and runoff and contact with soil, waterways, drains and sewers.

Disposal should be in accordance with applicable regional, national and local laws and regulations. Local regulations may be more stringent than regional or national requirements.

The information presented below only applies to the material as supplied. The identification based on characteristic(s) or listing may not apply if the material has been used or otherwise contaminated. It is the responsibility of the waste generator to determine the toxicity and physical properties of the material generated to determine the proper waste identification and disposal methods in compliance with applicable regulations.

Refer to Section 7: HANDLING AND STORAGE and Section 8: EXPOSURE CONTROLS/PERSONAL PROTECTION for additional handling information and protection of employees.

Date of issue: 09/01/2015
Section 14. Transport information

Regulatory information
DOT / IMDG / IATA : Not regulated.

Section 15. Regulatory information

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

U.S. Federal regulations
United States inventory (TSCA 8b): All components are listed or exempted.
Clean Water Act (CWA) 311: Edetic acid

Clean Air Act Section 112 (b) Hazardous Air Pollutants (HAPs) : Not listed
Clean Air Act Section 602 Class I Substances : Not listed
Clean Air Act Section 602 Class II Substances : Not listed
DEA List I Chemicals (Precursor Chemicals) : Not listed
DEA List II Chemicals (Essential Chemicals) : Not listed

SARA 302/304
Composition/information on ingredients
No products were found.

SARA 304 RQ : Not applicable.

SARA 311/312
Classification : Not applicable.
Composition/information on ingredients
No products were found.

State regulations
Massachusetts : None of the components are listed.
New York : None of the components are listed.
New Jersey : None of the components are listed.
Pennsylvania : None of the components are listed.
California Prop. 65 : None of the components are listed.

Canada inventory
International regulations
International lists
Australia inventory (AICS): All components are listed or exempted.
China inventory (IECSC): All components are listed or exempted.
Japan inventory: All components are listed or exempted.
Korea inventory: All components are listed or exempted.
Malaysia Inventory (EHS Register): Not determined.
New Zealand Inventory of Chemicals (NZIoC): All components are listed or exempted.
Philippines inventory (PICCS): All components are listed or exempted.
Taiwan inventory (CSNN): All components are listed or exempted.

Date of issue : 09/01/2015
## Section 15. Regulatory information

<table>
<thead>
<tr>
<th>Chemical Weapons Convention List Schedule</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>I Chemicals</td>
<td>Not listed</td>
</tr>
<tr>
<td>Chemical Weapons Convention List Schedule</td>
<td></td>
</tr>
<tr>
<td>II Chemicals</td>
<td>Not listed</td>
</tr>
<tr>
<td>Chemical Weapons Convention List Schedule</td>
<td></td>
</tr>
<tr>
<td>III Chemicals</td>
<td>Not listed</td>
</tr>
</tbody>
</table>

## Section 16. Other information

### History
- **Date of issue**: 2015-09-01
- **Date of previous issue**: No previous validation
- **Version**: 1

- Indicates information that has changed from previously issued version.

### Notice to reader

Disclaimer: The information contained in this document is based on Agilent's state of knowledge at the time of preparation. No warranty as to its accurateness, completeness or suitability for a particular purpose is expressed or implied.